Lipopolysaccharide, Immune Activation, and Liver Abnormalities in HIV/Hepatitis B Virus (HBV)-Coinfected Individuals Receiving HBV-Active Combination Antiretroviral Therapy
Lipopolysaccharide, Immune Activation, and Liver Abnormalities in HIV/Hepatitis B Virus (HBV)-Coinfected Individuals Receiving HBV-Active Combination Antiretroviral Therapy
复制标题
DOI：
10.1093/infdis/jiu119
复制
发表时间：
2014-09-01
影响因子：
6.4
通讯作者：
Lewin, Sharon R.
中科院分区：
文献类型：
--
作者：
Crane, Megan;Avihingsanon, Anchalee;Lewin, Sharon R.
我们研究了人类免疫缺陷病毒（HIV）/B型肝炎病毒（HBV）合并感染中微生物易位、免疫激活和肝脏疾病之间的关系。HIV/HBV合并感染患者的脂多糖（LPS）、可溶性CD 14、CXCL 10和CCL-2水平升高。接受HBV活性联合抗逆转录病毒治疗（cART）后，LPS、可溶性CD 14和CCL-2水平下降，但CXCL 10水平仍升高。在肝活检中没有与肝脏疾病严重程度相关的标志物（n = 96），但CXCL 10、白细胞介素6（IL-6）、白细胞介素10（IL-10）、肿瘤坏死因子α和干扰素γ（IFN-γ）均与接受HBV活性cART期间肝酶水平升高相关。在体外用IFN-γ和LPS刺激肝细胞系诱导了CXCL 10产生的显著协同增加。LPS可能通过刺激CXCL 10的持续产生而导致肝脏疾病。
We investigated the relationship between microbial translocation, immune activation, and liver disease in human immunodeficiency virus (HIV)/hepatitis B virus (HBV) coinfection. Lipopolysaccharide (LPS), soluble CD14, CXCL10, and CCL-2 levels were elevated in patients with HIV/HBV coinfection. Levels of LPS, soluble CD14, and CCL-2 declined following receipt of HBV-active combination antiretroviral therapy (cART), but the CXCL10 level remained elevated. No markers were associated with liver disease severity on liver biopsy (n = 96), but CXCL10, interleukin 6 (IL-6), interleukin 10 (IL-10), tumor necrosis factor a, and interferon gamma (IFN-gamma) were all associated with elevated liver enzyme levels during receipt of HBV-active cART. Stimulation of hepatocyte cell lines in vitro with IFN-gamma and LPS induced a profound synergistic increase in the production of CXCL10. LPS may contribute to liver disease via stimulating persistent production of CXCL10.